Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (4561)	4/6/1998 10:42:00 PM
From: SnowShredder	Read Replies (1) \| Respond to of 9719

RB, Here is a link that I snagged from the Cephalon Thread: <l> Message 3974698 </l> Personally I think that it is a toss up in that they didn't say no Thurs. @ the meeting, but the FDA also recommended that they get more info last time...which they didn't. I hope this helps. Best of Luck, Where'd He Go?

To: Russian Bear who wrote (4561)	4/6/1998 11:06:00 PM
From: Rocketman	Read Replies (2) \| Respond to of 9719

Avoidance of reality comes to mind. The FDA just doesn't want to deal with this one and is doing anything it can to delay it. If they disapprove of it, the patients will scream to Congress, if they approve it their bureaucrats will scream that they were ignored. The answer is to sweep it under the rug repeatedly and hope that either more definitive data or a better product comes along. Rman

To: Russian Bear who wrote (4561)	4/6/1998 11:29:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 9719

RB, Michasl Murphy opines that since the FDA has a late May deadline to reach a decision, the Apr 9 meeting was originally set up to allow the review panel meeting then, to hand up an opinion in a reasonable time. He thinks the cancellation avoids the need for the FDA to have to hear a probable panel rejection,thereby enabling an unopposed positive FDA decision, since the panel will no longer have sufficient time to meet & hand up their objection. To be safe, he also allows for the FDA to extend the timeframe, but gives it a low probability. Be forewarned, this is my interpretation of his thesis. I have no position currently in the stock.